Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization ...
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...
Evaxion’s proprietary AI-Immunology platform has shown in clinical trials that it can select clinically relevant cancer ...
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.
The current status of the Biosecure Act is that it was passed ​ by the US House of Representatives on Sep 9, with a vote of ...
Artificial intelligence (AI) is now infiltrating core industries and according to Forbes, the market is expected to reach a value of $22.6 billion dollars by next year (2025). One area it is thriving ...
Months after divesting seven European sites, the Swedish contract development and manufacturing organisation (CDMO) Recipharm ...
The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback